Replies to post #3360 on Biotech Values

[DewDiligence]

>> I like the idea of reimbursement being in place, patients identified and being treated and clamoring for something better. <<

We already have all that with Visudyne, including the IV delivery.

From an investment standpoint, I’d prefer not to see intravitreal injections get established at the standard of care.